Benzodiazepine-Associated Carcinogenesis: Focus on Lorazepam-Associated Cancer Biomarker Changes in Overweight Individuals
| Autor: | Pei-Shen Ho, Yu-Ting Tseng, Chih-Sung Liang, Shu-Li Cheng, Ta-Chuan Yeh, Shih-Chieh Ku |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Placental growth factor Carcinogenesis medicine.medical_treatment Lorazepam medicine.disease_cause Benzodiazepines 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Epidermal growth factor medicine Biological Psychiatry Cancer business.industry Growth factor Overweight Endoglin medicine.disease Vascular endothelial growth factor Psychiatry and Mental health 030104 developmental biology chemistry 030220 oncology & carcinogenesis Cancer research Original Article Cancer biomarkers business |
| Zdroj: | Psychiatry Investigation |
| ISSN: | 1976-3026 1738-3684 |
| DOI: | 10.30773/pi.2018.05.02.1 |
| Popis: | Objective Cellular, animal, and human epidemiological studies suggested that benzodiazepines increase the risk of cancer and cancer mortality. Obesity is also clearly linked to carcinogenesis. However, no human studies have examined benzodiazepine-associated carcinogenesis as assessed by changes in cancer biomarkers. Methods A total of 19 patients were recruited, and received a 6-week treatment of 0.5 mg lorazepam. The measured cancer biomarkers were angiopoietin-2 (ANG-2), soluble CD40 ligand, epidermal growth factor, endoglin, soluble Fas ligand (sFASL), heparin-binding EGF-like growth factor (HB-EGF), insulin-like growth factor binding protein, interleukin (IL)-6, IL-8, IL-18, plasminogen activator inhibitor (PLGF), placental growth factor, transforming growth factor (TGF)-α, tumor necrosis factor (TNF)-α, urokinase-type plasminogen (uPA), vascular endothelial growth factor (VEGF)-A, VEGF-C, and VEGF-D. Results Six cancer biomarkers were significantly increased in all patients as a whole. The subgroup analysis revealed a distinct pattern of change. Overweight patients showed a significant increase in 11 cancer biomarkers, including ANG-2, sFASL, HB-EGF, IL-8, PLGF, TGF-α, TNF-α, uPA, VEGF-A, VEGF-C, and VEGF-D. However, normal-weight patients did not show any changes in cancer biomarkers. Conclusion Adiposity may have primed the carcinogenic potential, leading to lorazepam-associated carcinogenesis in overweight patients. Epidemiological studies addressing this issue should consider the potential modulator contributing to benzodiazepine-associated carcinogenesis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|